Aidigong Maternal & Child Health Limited provided earnings guidance for the six months ended June 30, 2023. For the period, the company expected to record a gross profit of approximately HKD 93 million for the Period, representing an increase of approximately HKD 38 million or 69.1% as compared to the corresponding period in 2022 and a net loss of approximately HKD 23 million for the Period, representing a decrease of approximately HKD 39 million or 62.9% as compared to the net loss recorded for the corresponding period in 2022. The Group's adjusted EBITDA for the Period will increase HKD 36 million to HKD 31 million as compared to the corresponding period in 2022.

During the Period, the increase in gross profit, reduction in net loss and improved EBITDA of the Group are mainly attributable to the following reasons: new stores are operated under the ultra-light asset model, which further reduce the initial investment of new stores and optimize the financial model of mature stores, resulting in a substantial increase in gross profit; the operation of Aidigong is gradually getting out of the impact of the epidemic and is in a steady recovery phase which returns to profitability; and the postpartum care services business is using innovative marketing approach to improve marketing efficiency, and hence sales and marketing expenses have decreased compared with the corresponding period in 2022. With the implementation of the Group's strategy to capture high-quality markets, the Board is confident in the Group's business development and prospects.